SCHEMBL335983

SCHEMBL335983

COc1cc2cc(C(=O)O)[nH]c2cc1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 1/20 0.70
SRD5A2 P31213 1/20 0.70
KDM4E B2RXH2 3/20 0.59
HPGD P15428 3/20 0.59
ALDH1A1 P00352 2/20 0.59
LMNA P02545 2/20 0.59
RXFP1 Q9HBX9 2/20 0.58
GPR35 Q9HC97 1/20 0.58
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
EHMT2 Q96KQ7 1/20 0.53
PIN1 Q13526 1/20 0.53
POLB P06746 3/20 0.50
EIF4A3 P38919 2/20 0.50
SMAD3 P84022 1/20 0.50
F7 P08709 1/20 0.49
F3 P13726 1/20 0.49
PDPK1 O15530 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3100380 0.88 SRD5A2 (0.58) SRD5A1SRD5A2KDM4EHPGDALDH1A1
SCHEMBL6285596 0.88 GPR35 (0.67) SRD5A1SRD5A2KDM4EHPGDALDH1A1
SCHEMBL30779684 0.88 GPR35 (0.67) SRD5A1SRD5A2KDM4EHPGDALDH1A1
SCHEMBL29379466 0.88 GPR35 (0.67) SRD5A1SRD5A2KDM4EHPGDALDH1A1
SCHEMBL3361096 0.88 GPR35 (0.67) SRD5A1SRD5A2KDM4EHPGDALDH1A1
SCHEMBL18239638 0.88 SRD5A1 (0.58) SRD5A1SRD5A2KDM4EHPGDALDH1A1
SCHEMBL1144612 0.87 EIF4A3 (0.60) SRD5A1SRD5A2KDM4EHPGDALDH1A1
SCHEMBL19331953 0.87 SRD5A2 (0.56) SRD5A1SRD5A2KDM4EHPGDALDH1A1
SCHEMBL1144949 0.87 SRD5A2 (0.56) SRD5A1SRD5A2KDM4EHPGDALDH1A1
SCHEMBL13173649 0.87 SRD5A2 (0.56) SRD5A1SRD5A2KDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9928968-B2 Melanins as active components in energy storage materials CARNEGIE MELLON UNIVERSITY (US) 2018-03-27 US claimed
EP-2582351-B1 HAIR DYEING PROCESS USING A COMPOSITION COMPRISING AT LEAST ONE INDOLE OR INDOLINE COMPOUND, A METAL SALT, HYDROGEN PEROXIDE AND A BASIFYING AGENT L'ORÉAL (FR) 2017-08-02 EP claimed
EP-2948454-B1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) 2017-05-31 EP claimed
US-20160049262-A1 Melanins as Active Components in Energy Storage Materials CARNEGIE MELLON UNIVERSITY 2016-02-18 US claimed
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed
CN-101516834-A Isoserine derivatives for use as coagulation factor ixa inhibitors SANOFI AVENTIS (FR) 2009-08-26 CN claimed
EP-4660193-A1 INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2025-12-10 EP disclosed
US-20250297834-A1 Impact Resistant Material BARANOWITZ STEVEN (US) 2025-09-25 US disclosed
US-12352535-B2 Impact resistant material BARANOWITZ STEVEN (US) 2025-07-08 US disclosed
WO-2024162746-A1 INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF 한국화학연구원 2024-08-08 WO disclosed
US-20240085153-A1 Enhanced Impact Resistant Material BARANOWITZ STEVEN (US) 2024-03-14 US disclosed
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2024-01-18 US disclosed
US-5482960-A Nonpeptide endothelin antagonists WARNER-LAMBERT COMPANY (US) 1996-01-09 US disclosed
EP-0507861-A1 DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS. UPJOHN CO (US) 1992-10-14 EP disclosed
EP-0234540-B1 HEAT-SENSITIVE RECORDING MATERIAL KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) 1991-10-16 EP disclosed
WO-1991009849-A1 DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS THE UPJOHN COMPANY (US) 1991-07-11 WO disclosed
US-4731353-A METAL SALT OF INDOLE-2-CARBOXYLIC ACID COLOR DEVELOPER KANZAKI PAPER MANUFACTURING COMPANY, LIMITED (JP) 1988-03-15 US disclosed
EP-0234540-A2 Heat-sensitive recording material KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) 1987-09-02 EP disclosed
US-4599357-A 1-mercaptoalkanoylindoline-2-carboxylic acids CIBA-GEIGY CORPORATION (US) 1986-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 SRD5A1 795/4885SRD5A2 1196/4885KDM4E 3870/4885
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS MAOA, DRD2, MAOB SRD5A1 1217/4885SRD5A2 1223/4885KDM4E 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.